CCM
CLDX icon

Consonance Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Consonance Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-50,117
Closed -$19M – 30
2015
Q2 		$19M Buy
+50,117
New +$19.9M 1.9% 15

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Consonance Capital Management's CLDX Position: Q3 2015 in Review

Consonance Capital Management sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 50,117 shares — an estimated $19M sold.

Consonance Capital Management first reported a position in CLDX in Q2 2015 and held it in 1 quarter. The position peaked at $19M in Q2 2015. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

  • Consonance Capital Management reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Consonance Capital Management sold 50,117 Celldex Therapeutics shares in Q3 2015, an estimated $19M.
  • Consonance Capital Management first reported a position in Celldex Therapeutics in Q2 2015 and held it in 1 quarter.
  • Consonance Capital Management's Celldex Therapeutics position peaked at $19M in Q2 2015.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on Consonance Capital Management's 13F filing for Q3 2015, filed 9 Nov 2015.